For patients with nonmetastatic prostate cancer, focal therapy use has remained uncommon across risk groups, and its use was defined as inappropriate in about half of recipients, according to a research letter published online Aug. 13 in the JAMA.
A study published in JAMA reveals that focal therapy use remains uncommon in nonmetastatic prostate cancer patients, with only 1.3% of the 1.18 million U.S. patients included in the research receiving this treatment. While focal therapy use did increase modestly in favorable intermediate-risk disease, it declined in unfavorable intermediate-, high-, and very high-risk disease categories.
This shift in usage highlights the need for evidence-based adoption of treatments that match patients' likelihood of benefiting from the therapy.
Brief written by urgent.news from Medical Xpress's own syndicated text.
Machine-written — may contain errors; check the original before relying on it.
(MedPage Today) -- More than 6 years after the COVID-19 pandemic began, its effects have continued. In March 2024, roughly 17 million adults (7% of all U.S.
A pioneering Red Cross service in San Fulgencio is helping elderly, disabled and vulnerable residents remain safe and supported in their own homes — while providing vital companionship to those facing…
A new study finds that taking the antidepressant escitalopram in the days leading up to menstruation reduces irritability, anger, and impulsive behavioral responses in women suffering from severe premenstrual symptoms.
The Panvel Municipal Corporation (PMC) has intensified preventive measures to curb the spread of mosquito-borne diseases such as dengue, malaria and chikungunya across its jurisdiction, with regular surveys being conducted to identify mosquito breeding sites.
